Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03084014 with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT02109445Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nirogacestat in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting Toxicities and Overall Survival up to 5 years. Started Sep 2014; status: terminated.
02
Drugs
nirogacestat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02109445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109445.